Researchers injected Ewing sarcoma cells into mice to determine the effects of exercise on doxorubicin efficacy and treatment-related cardiotoxicity.
Dexrazoxane has cardioprotective properties that can prevent long-term cardiotoxicity in pediatric patients receiving chemotherapy, according to a review of the medical literature on cardiotoxic effects of anthracycline treatment.
Trastuzumab-related cardiotoxicity was far lower in Taiwanese women with breast cancer compared with previously published results, according to recent study data.
A study examined the relation between various forms of breast cancer therapies and risk of congestive heart failure.
Breast cancer patients with BRCA 1/2 gene mutations do not have an increased risk of anthracycline-induced cardiac toxicity.
Sign Up for Free e-newsletters
- Chemotherapy-Related Fatigue Linked to Levothyroxine Use in Breast Cancer
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
- Zinc Sulfate Improves Chemotherapy-Induced Mucositis Outcomes in Leukemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|